Search

everythinglearnresearchcommunity

for

Search:↓

Women with the NIH type of PCOS have more obesity and higher risk of diabetes and heart disease than those with other types of PCOS.

Chemicals and body size might change when puberty starts and progresses, but more research is needed to confirm this.

The Endocrine Society advised against routine testosterone therapy for women, citing a need for more research on long-term safety and a clear definition of androgen deficiency.

Chemotherapy can cause various skin reactions, with hair loss being the most common, and proper diagnosis and treatment of these reactions are important.

The document likely offers guidance on treating a woman's excessive hair growth, considering her symptoms and obesity.

The document concludes that insulin resistance is key in PCOS development and early treatment is crucial to prevent complications.

PCOS is a complex disorder in women that can lead to various health risks and requires personalized treatment.

The NAMS 2014 recommendations guide healthcare providers on treating health issues in midlife women, emphasizing individualized care and informed decision-making.

The Rotterdam Study updated its design and objectives in 2012, providing insights into various diseases in the elderly, including skin cancer, bone health, liver disease, neurological and psychiatric conditions, and respiratory issues.

The report recommends personalized treatment for women's sexual dysfunctions and more research on effective therapies.

Blocking the enzyme 5α-reductase can shrink the prostate and help treat enlarged prostate issues.

Creating stronger blockers for skin enzymes might lead to better treatment for conditions like acne and excessive hair growth.

Cyproterone acetate is effective for acne but less so for hirsutism and alopecia, with some side effects and quick menstrual cycle recovery after treatment.

The document concludes that the 5 alpha-reductase enzymes are important in steroid metabolism and related to various human diseases, with inhibitors used to treat conditions like male pattern baldness and prostate issues.

Minoxidil and finasteride treat hair loss in men, while minoxidil treats hair loss in women.

Androgens can both increase and decrease hair growth in different parts of the body.

Lifestyle changes can improve body composition, excess male hormone levels, and insulin resistance in women with PCOS.

High levels of male hormones, insulin resistance, and obesity are closely linked and worsen polycystic ovary syndrome, but more research is needed to improve treatments.

Stress stops hair growth in mice by causing early hair growth phase end and harmful inflammation through a specific nerve-related pathway.

Opioid painkillers can cause many side effects, including breathing problems and addiction, but are generally considered safe when used properly.

Some treatments can help with a hair loss condition called alopecia areata, but none ensure lasting results; choices depend on the person, with JAK inhibitors showing promise for severe cases.

Androgens can help prevent memory problems caused by apoE4.

Lower doses of treatments for hirsutism and acne in PCOS are effective and cause fewer side effects.

Estrogens significantly influence hair growth by interacting with receptors in hair follicles and may help regulate the hair growth cycle.

Androgens can cause hair growth in some areas and hair loss on the scalp.

Lichen planus is a skin condition that can resolve on its own, is linked to hepatitis C, and increases the risk of skin cancer.

Male and female skin differ due to hormones, affecting conditions like hair loss, acne, and skin cancer, and suggesting a need for gender-specific treatments.

Effective treatments for male pattern baldness include oral finasteride and topical minoxidil, while topical minoxidil is best for female pattern baldness.

Guidelines for diagnosing common hair loss include detailed history, clinical examination, and various diagnostic techniques.

The document concludes that more research is needed to better understand and treat primary cicatricial alopecias, and suggests a possible reclassification based on molecular pathways.